Table 2.
Prevalence of aPS/PT IgG and IgM antibodies by disease group.
| Total | APS | Non-APS | SLE | Others | |
|---|---|---|---|---|---|
| n = 103 | n = 25 | n = 22 | n = 30 | n = 26 | |
| |||||
| First sample | 15 (15) | 8 (32) | 1 (5) | 4 (13) | 2 (8) |
| Second sample | 13 (13) | 7 (28) | 1 (5) | 3 (10) | 2 (8) |
| Both | 9 (9) | 7 (28) | 0 (0) | 2 (7) | 0 (0) |
| At least one positive | 19/103 (18) | 8/25 (32) | 2/22 (9) | 5/30 (17) | 4/26 (15) |
| aPS/PT IgM | |||||
| First sample | 45 (44) | 18 (72) | 4 (18) | 13 (43) | 10 (38) |
| Second sample | 45 (44) | 19 (76) | 5 (22) | 12 (40) | 9 (35) |
| Both | 38 (37) | 18 (72) | 4 (18) | 9 (30) | 7 (27) |
| At least one positive | 52/103 (51) | 19/25 (76) | 5/22 (23) | 16/30 (53) | 12/26 (46) |
| aPS/PT IgM+ IgG- at first sample | 31/103 (30) | 10/25 (40) | 4/22 (18) | 9/30 (30) | 8/26 (31) |
Values of categorical variables are expressed as number and (percentage). Second samples were collected > 12 weeks apart.
APS, anti-phospholipid syndrome; SLE, systemic lupus erythematous; aPS/PT, anti-phosphatidylserine/prothrombin antibodies.